<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37176044</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle><i>Clostridia</i> and Enteroviruses as Synergistic Triggers of Type 1 Diabetes Mellitus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8336</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24098336</ELocationID><Abstract><AbstractText>What triggers type 1 diabetes mellitus (T1DM)? One common assumption is that triggers are individual microbes that mimic autoantibody targets such as insulin (INS). However, most microbes highly associated with T1DM pathogenesis, such as coxsackieviruses (COX), lack INS mimicry and have failed to induce T1DM in animal models. Using proteomic similarity search techniques, we found that COX actually mimicked the INS receptor (INSR). <i>Clostridia</i> were the best mimics of INS. <i>Clostridia</i> antibodies cross-reacted with INS in ELISA experiments, confirming mimicry. COX antibodies cross-reacted with INSR. <i>Clostridia</i> antibodies further bound to COX antibodies as idiotype-anti-idiotype pairs conserving INS-INSR complementarity. Ultraviolet spectrometry studies demonstrated that INS-like <i>Clostridia</i> peptides bound to INSR-like COX peptides. These complementary peptides were also recognized as antigens by T cell receptor sequences derived from T1DM patients. Finally, most sera from T1DM patients bound strongly to inactivated <i>Clostridium sporogenes</i>, while most sera from healthy individuals did not; T1DM sera also exhibited evidence of anti-idiotype antibodies against idiotypic INS, glutamic acid decarboxylase, and protein tyrosine phosphatase non-receptor (islet antigen-2) antibodies. These results suggest that T1DM is triggered by combined enterovirus-<i>Clostridium</i> (and possibly combined Epstein-Barr-virus-<i>Streptococcal</i>) infections, and the probable rate of such co-infections approximates the rate of new T1DM diagnoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Root-Bernstein</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3298-9306</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiles</LastName><ForeName>Kaylie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziehl</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turke</LastName><ForeName>Miah</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3091-2356</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Chicago, Chicago, IL 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietrowicz</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061386">Insulin, Regular, Human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061386" MajorTopicYN="N">Insulin, Regular, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003013" MajorTopicYN="N">Clostridium</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COX</Keyword><Keyword MajorTopicYN="N">Clostridium</Keyword><Keyword MajorTopicYN="N">T cell receptors</Keyword><Keyword MajorTopicYN="N">circulating immune complexes</Keyword><Keyword MajorTopicYN="N">complementary antigens</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">idiotype–anti-idiotype</Keyword><Keyword MajorTopicYN="N">synergism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37176044</ArticleId><ArticleId IdType="pmc">PMC10179352</ArticleId><ArticleId IdType="doi">10.3390/ijms24098336</ArticleId><ArticleId IdType="pii">ijms24098336</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mallone R., Brezar V., Boitard C. T cell recognition of autoantigens in human type 1 diabetes: Clinical perspectives. Clin. Dev. Immunol. 2011;2011:513210. doi: 10.1155/2011/513210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/513210</ArticleId><ArticleId IdType="pmc">PMC3140193</ArticleId><ArticleId IdType="pubmed">21785617</ArticleId></ArticleIdList></Reference><Reference><Citation>Krischer J.P., Liu X., Lernmark Å., Hagopian W.A., Rewers M.J., She J.X., Toppari J., Ziegler A.G., Akolkar B., TEDDY Study Group Predictors of the Initiation of Islet Autoimmunity and Progression to Multiple Autoantibodies and Clinical Diabetes: The TEDDY Study. Diabetes Care. 2022;45:2271–2281. doi: 10.2337/dc21-2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc21-2612</ArticleId><ArticleId IdType="pmc">PMC9643148</ArticleId><ArticleId IdType="pubmed">36150053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer W., Veijola R., Lempainen J., Kiviniemi M., Härkönen T., Toppari J., Knip M., Gyenesei A., Ilonen J. Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood. J. Clin. Endocrinol. Metab. 2019;104:4521–4530. doi: 10.1210/jc.2019-00421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2019-00421</ArticleId><ArticleId IdType="pubmed">31120497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.W., Won H.K., Seok H., Lee B.W., Jung C.H., Lee W.J., Kim J.H. High prevalence of both anti-INS and anti-INS receptor antibodies in Korean patients with INS autoimmune syndrome. Diabetes Res. Clin. Pract. 2012;98:e12–e15. doi: 10.1016/j.diabres.2012.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2012.09.019</ArticleId><ArticleId IdType="pubmed">23000370</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackard W.G., Anderson J.H., Mullinax F. Anti-INS receptor antibodies and diabetes. Ann. Intern. Med. 1977;86:584–585. doi: 10.7326/0003-4819-86-5-584.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-86-5-584</ArticleId><ArticleId IdType="pubmed">851310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S.M., Faiman C., Dean H.J. INS and INS-receptor autoantibodies in children with newly diagnosed IDDM before INS therapy. Diabetes. 1987;36:420–425. doi: 10.2337/diab.36.4.420.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.36.4.420</ArticleId><ArticleId IdType="pubmed">3817302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn C.R., Kasuga M., King G.L., Grunfeld C. Ciba Foundation Symposium. Wiley; Hoboken, NJ, USA: 1982. Autoantibodies to INS receptors in man: Immunological determinants and mechanism of action; pp. 91–113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470720721.ch7</ArticleId><ArticleId IdType="pubmed">6183063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochet N., Sadoul J.L., Ferrua B., Kubar J., Tanti J.F., Bougnères P., Vialettes B., Van Obberghen E., Le Marchand-Brustel Y., Freychet P. Autoantibodies to the INS receptor are infrequent findings in type 1 (INS-dependent) diabetes mellitus of recent onset. Diabetologia. 1990;33:411–416. doi: 10.1007/BF00404090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00404090</ArticleId><ArticleId IdType="pubmed">2205528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gergely A., Korányl L., Halmos T., Zsombók M., Péterfy F., Csizér F., Salamon F., Takó J. Anti-glucagon antibodies in diabetes mellitus. Ann. Immunol. Hung. 1973;17:231–233.</Citation><ArticleIdList><ArticleId IdType="pubmed">4808018</ArticleId></ArticleIdList></Reference><Reference><Citation>Asplin C.M., Hollander P., Pecoraro R.E., Brodsky J., Palmer J.P. INS, pancreatic polypeptide, and glucagon antibodies in INS-dependent diabetes mellitus. Diabetes Care. 1981;4:337–342. doi: 10.2337/diacare.4.3.337.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.4.3.337</ArticleId><ArticleId IdType="pubmed">7047110</ArticleId></ArticleIdList></Reference><Reference><Citation>Caforio A.L., Iliceto S. Genetically determined myocarditis: Clinical presentation and immunological characteristics. Curr. Opin. Cardiol. 2008;23:219–226. doi: 10.1097/HCO.0b013e3282fbf572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCO.0b013e3282fbf572</ArticleId><ArticleId IdType="pubmed">18382209</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.S., Ligons D.L., Rose N.R. Genetic complexity of autoimmune myocarditis. Autoimmun. Rev. 2008;7:168–173. doi: 10.1016/j.autrev.2007.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2007.11.010</ArticleId><ArticleId IdType="pmc">PMC2233796</ArticleId><ArticleId IdType="pubmed">18190873</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Belle T.L., Coppieters K.T., von Herrath M.G. Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol. Rev. 2011;91:79–118. doi: 10.1152/physrev.00003.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00003.2010</ArticleId><ArticleId IdType="pubmed">21248163</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilherme L., Köhler K.F., Postol E., Kalil J. Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann. Pediatr. Cardiol. 2011;4:13–21. doi: 10.4103/0974-2069.79617.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0974-2069.79617</ArticleId><ArticleId IdType="pmc">PMC3104525</ArticleId><ArticleId IdType="pubmed">21677799</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugliese A. The multiple origins of Type 1 diabetes. Diabet. Med. 2013;30:135–146. doi: 10.1111/dme.12081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.12081</ArticleId><ArticleId IdType="pubmed">23181718</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschard K. The etiology and pathogenesis of type 1 diabetes—A personal, non-systematic review of possible causes, and interventions. Front. Endocrinol. 2022;13:876470. doi: 10.3389/fendo.2022.876470.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.876470</ArticleId><ArticleId IdType="pmc">PMC9452747</ArticleId><ArticleId IdType="pubmed">36093076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannering S.I., Pathiraja V., Kay T.W. The case for an autoimmune aetiology of type 1 diabetes. Clin. Exp. Immunol. 2016;183:8–15. doi: 10.1111/cei.12699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12699</ArticleId><ArticleId IdType="pmc">PMC4687512</ArticleId><ArticleId IdType="pubmed">26313217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober D., Sauter P. Pathogenesis of type 1 diabetes mellitus: Interplay between enterovirus and host. Nat. Rev. Endocrinol. 2010;6:279–289. doi: 10.1038/nrendo.2010.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2010.27</ArticleId><ArticleId IdType="pubmed">20351698</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaidane H., Hober D. Role of COX B4 in the pathogenesis of type 1 diabetes. Diabetes Metab. 2008;34:537–548. doi: 10.1016/j.diabet.2008.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2008.05.008</ArticleId><ArticleId IdType="pubmed">18951821</ArticleId></ArticleIdList></Reference><Reference><Citation>Richer M.J., Horwitz M.S. COX infection as an environmental factor in the etiology of type 1 diabetes. Autoimmun. Rev. 2009;8:611–615. doi: 10.1016/j.autrev.2009.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.02.006</ArticleId><ArticleId IdType="pubmed">19393207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipris D. Epidemiology of type 1 diabetes and what animal models teach us about the role of viruses in disease mechanisms. Clin. Immunol. 2009;131:11–23. doi: 10.1016/j.clim.2008.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.12.011</ArticleId><ArticleId IdType="pubmed">19185542</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms R.Z., Ostlund K.R., Cabrera M.S., Edwards E., Fisher M., Sarvetnick N. Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes. Front. Immunol. 2020;11:1922. doi: 10.3389/fimmu.2020.01922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01922</ArticleId><ArticleId IdType="pmc">PMC7523316</ArticleId><ArticleId IdType="pubmed">33042112</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Zhao B., Zhang Z., Dai X., Zhang Y., Cui L. Association between enterovirus infection and clinical type 1 diabetes mellitus: Systematic review and meta-analysis of observational studies. Epidemiol. Infect. 2021;150:e23. doi: 10.1017/S0950268821002442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268821002442</ArticleId><ArticleId IdType="pmc">PMC8851353</ArticleId><ArticleId IdType="pubmed">35144715</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M., Knip M., Hyöty H., Kulmala P., Hiltunen M., Vähäsalo P., Hovi T., Akerblom H.K., Childhood Diabetes in Finland (DiMe) Study Group Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. J. Med. Virol. 1998;56:74–78. doi: 10.1002/(SICI)1096-9071(199809)56:1&lt;74::AID-JMV12&gt;3.0.CO;2-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199809)56:1&lt;74::AID-JMV12&gt;3.0.CO;2-W</ArticleId><ArticleId IdType="pubmed">9700636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung W.C., Rawlinson W.D., Craig M.E. Enterovirus infection and type 1 diabetes mellitus: Systematic review and meta-analysis of observational molecular studies. BMJ. 2011;342:d35. doi: 10.1136/bmj.d35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d35</ArticleId><ArticleId IdType="pmc">PMC3033438</ArticleId><ArticleId IdType="pubmed">21292721</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg E., Krause I. Infection and type 1 diabetes mellitus—A two edged sword? Autoimmun. Rev. 2009;8:682–686. doi: 10.1016/j.autrev.2009.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.02.017</ArticleId><ArticleId IdType="pubmed">19393195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.W., Jun H.S. Viruses in type 1 diabetes: Brief review. ILAR J. 2004;45:343–348. doi: 10.1093/ilar.45.3.343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ilar.45.3.343</ArticleId><ArticleId IdType="pubmed">15229381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammi N., Karvonen M., Tuomilehto J. Do microbes have a causal role in type 1 diabetes? Med. Sci. Monit. 2005;11:RA63–RA69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15735577</ArticleId></ArticleIdList></Reference><Reference><Citation>Laverdant C., Fromantin M. Le diabète de l’hépatite virale. A propos de 20 observations émanant d’un groupement de 4,456 malades [Diabetes after viral hepatitis. 20 cases out of a group of 4,456 patients] Ann. Gastroenterol. Hepatol. 1970;6:101–109. (In French)</Citation><ArticleIdList><ArticleId IdType="pubmed">5505492</ArticleId></ArticleIdList></Reference><Reference><Citation>Sechi L.A., Rosu V., Pacifico A., Fadda G., Ahmed N., Zanetti S. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. Clin. Vaccine Immunol. 2008;15:320–326. doi: 10.1128/CVI.00381-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00381-07</ArticleId><ArticleId IdType="pmc">PMC2238046</ArticleId><ArticleId IdType="pubmed">18077612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosu V., Ahmed N., Paccagnini D., Gerlach G., Fadda G., Hasnain S.E., Zanetti S., Sechi L.A. Specific immunoassays confirm association of Mycobacterium avium Subsp. paratuberculosis with Type-1 but not Type-2 diabetes mellitus. PLoS ONE. 2009;4:e4386. doi: 10.1371/journal.pone.0004386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004386</ArticleId><ArticleId IdType="pmc">PMC2636876</ArticleId><ArticleId IdType="pubmed">19204799</ArticleId></ArticleIdList></Reference><Reference><Citation>Marietti M., Gasbarrini A., Saracco G., Pellicano R. Helicobacter pylori infection and diabetes mellitus: The 2013 state of art. Panminerva Med. 2013;55:277–281.</Citation><ArticleIdList><ArticleId IdType="pubmed">24088801</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley T., Dolton G., Brown P.E., Wall A., Wooldridge L., van den Berg H., Fuller A., Hopkins J.R., Crowther M.D., Attaf M., et al. GPU-Accelerated Discovery of Pathogen-Derived Molecular Mimics of a T-Cell INS Epitope. Front. Immunol. 2020;11:296. doi: 10.3389/fimmu.2020.00296.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00296</ArticleId><ArticleId IdType="pmc">PMC7058665</ArticleId><ArticleId IdType="pubmed">32184781</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura Y., Senju S., Maenaka K., Iwai L.K., Fujii S., Tabata H., Tsukamoto H., Hirata S., Chen Y.Z., Nishimura Y. Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for glutamic acid decarboxylase 65-specific TCRs. J. Immunol. 2003;170:947–960. doi: 10.4049/jimmunol.170.2.947.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.2.947</ArticleId><ArticleId IdType="pubmed">12517961</ArticleId></ArticleIdList></Reference><Reference><Citation>Giongo A., Gano K.A., Crabb D.B., Mukherjee N., Novelo L.L., Casella G., Drew J.C., Ilonen J., Knip M., Hyöty H., et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 2011;5:82–91. doi: 10.1038/ismej.2010.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2010.92</ArticleId><ArticleId IdType="pmc">PMC3105672</ArticleId><ArticleId IdType="pubmed">20613793</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.T., Davis-Richardson A.G., Giongo A., Gano K.A., Crabb D.B., Mukherjee N., Casella G., Drew J.C., Ilonen J., Knip M., et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE. 2011;610:e25792. doi: 10.1371/journal.pone.0025792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025792</ArticleId><ArticleId IdType="pmc">PMC3197175</ArticleId><ArticleId IdType="pubmed">22043294</ArticleId></ArticleIdList></Reference><Reference><Citation>De Goffau M.C., Luopajärvi K., Knip M., Ilonen J., Ruohtula T., Härkönen T., Orivuori L., Hakala S., Welling G.W., Harmsen H.J., et al. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes. 2013;62:1238–1244. doi: 10.2337/db12-0526.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-0526</ArticleId><ArticleId IdType="pmc">PMC3609581</ArticleId><ArticleId IdType="pubmed">23274889</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaarala O. Human intestinal microbiota and Type 1 Diabetes. Curr. Diabetes Rep. 2013;13:601–607. doi: 10.1007/s11892-013-0409-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-013-0409-5</ArticleId><ArticleId IdType="pubmed">23934614</ArticleId></ArticleIdList></Reference><Reference><Citation>Murri M., Leiva L., Gomez-Zumaquero J.M., Tinahones F.J., Cardona F. Gut microbiota in children with type 1 diabetes differs from that in healthy children: A case-control study.  [(accessed on 28 November 2022)];BMC Med. 2013 11:46.  doi: 10.1186/1741-7015-11-46. Available online:  http://www.biomedcentral.com/1741-7015/11/46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-46</ArticleId><ArticleId IdType="pmc">PMC3621820</ArticleId><ArticleId IdType="pubmed">23433344</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar S., Lin Y., Bettini M.L. Host-microbiota interactions shaping T-cell response and tolerance in type 1 diabetes. Front. Immunol. 2022;13:974178. doi: 10.3389/fimmu.2022.974178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.974178</ArticleId><ArticleId IdType="pmc">PMC9434376</ArticleId><ArticleId IdType="pubmed">36059452</ArticleId></ArticleIdList></Reference><Reference><Citation>Girdhar K., Huang Q., Chow I.T., Vatanen T., Brady C., Raisingani A., Autissier P., Atkinson M.A., Kwok W.W., Kahn C.R., et al. A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes. Proc. Natl. Acad. Sci. USA. 2022;119:e2120028119. doi: 10.1073/pnas.2120028119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2120028119</ArticleId><ArticleId IdType="pmc">PMC9351354</ArticleId><ArticleId IdType="pubmed">35878027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole D.K., Bulek A.M., Dolton G., Schauenberg A.J., Szomolay B., Rittase W., Trimby A., Jothikumar P., Fuller A., Skowera A., et al. Hotspot autoimmune T cell receptor binding underlies pathogen and INS peptide cross-reactivity. J. Clin. Investig. 2016;126:3626. doi: 10.1172/JCI89919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI89919</ArticleId><ArticleId IdType="pmc">PMC5004936</ArticleId><ArticleId IdType="pubmed">27525441</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Herrath M.G., Holz A., Homann D., Oldstone M.B. Role of viruses in type I diabetes. Semin. Immunol. 1998;10:87–100. doi: 10.1006/smim.1997.0108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/smim.1997.0108</ArticleId><ArticleId IdType="pubmed">9529659</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu P.-G., John T.-J. Alteration of immune response to coxsackie B3 virus by streptozotocin in dual-aetiology diabetes mellitus in mouse. Indian J. Exp. Biol. 1987;25:17–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">3038739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook S.H., Loria R.M., Madge G.E. Host factors in COX B4-induced pancreopathy. Lab Investig. 1982;46:377–382.</Citation><ArticleIdList><ArticleId IdType="pubmed">6279960</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.W., London W.T., Curfman B.L., Brown R.L., Notkins A.L. Coxsackie virus B4 produces transient diabetes in nonhuman primates. Diabetes. 1986;35:712–716. doi: 10.2337/diab.35.6.712.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.35.6.712</ArticleId><ArticleId IdType="pubmed">3011574</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter W., Mertens T., Schoel B., Muir P., Ritzkowsky A., Scherbaum W.A., Boehm B.O. Sequence homology of the diabetes-associated autoantigen glutamate decarboxylase with coxsackie B4-2C protein and heat shock protein 60 mediates no molecular mimicry of autoantibodies. J. Exp. Med. 1994;180:721–726. doi: 10.1084/jem.180.2.721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.180.2.721</ArticleId><ArticleId IdType="pmc">PMC2191584</ArticleId><ArticleId IdType="pubmed">7913951</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreugdenhil G.R., Batstra M.R., Aanstoot H.J., Melchers W.J., Galama J.M. Analysis of antibody responses against coxsackie virus B4 protein 2C and the diabetes autoantigen GAD(65) J. Med. Virol. 1999;59:256–261. doi: 10.1002/(SICI)1096-9071(199910)59:2&lt;256::AID-JMV21&gt;3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199910)59:2&lt;256::AID-JMV21&gt;3.0.CO;2-H</ArticleId><ArticleId IdType="pubmed">10459165</ArticleId></ArticleIdList></Reference><Reference><Citation>Marttila J., Juhela S., Vaarala O., Hyöty H., Roivainen M., Hinkkanen A., Vilja P., Simell O., Ilonen J. Responses of COX B4-specific T-cell lines to 2C protein-characterization of epitopes with special reference to the GAD65 homology region. Virology. 2001;284:131–141. doi: 10.1006/viro.2001.0917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2001.0917</ArticleId><ArticleId IdType="pubmed">11352674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine A.B., Lehtonen J., Nurminen N., Laitinen O.H., Oikarinen S., Huhtala H., Pakkanen O., Ruokoranta T., Hankaniemi M.M., Toppari J., et al. COX B1 infections are associated with the initiation of INS-driven autoimmunity that progresses to type 1 diabetes. Diabetologia. 2018;61:1193–1202. doi: 10.1007/s00125-018-4561-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4561-y</ArticleId><ArticleId IdType="pubmed">29404673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukreja A., Maclaren N.K. Current cases in which epitope mimicry is considered as a component cause of autoimmune disease: Immune-mediated (type 1) diabetes. Cell. Mol. Life Sci. 2000;57:534–541. doi: 10.1007/PL00000715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00000715</ArticleId><ArticleId IdType="pmc">PMC11147045</ArticleId><ArticleId IdType="pubmed">11130453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarugeri E., Dozio N., Meschi F., Pastore M.R., Bonifacio E. T cell responses to type 1 diabetes related peptides sharing homologous regions. J. Mol. Med. 2001;79:213–220. doi: 10.1007/s001090100194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001090100194</ArticleId><ArticleId IdType="pubmed">11409713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lönnrot M., Hyöty H., Knip M., Roivainen M., Kulmala P., Leinikki P., Akerblom H.K., Childhood Diabetes in Finland Study Group Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of COX B4. Clin. Exp. Immunol. 1996;104:398–405. doi: 10.1046/j.1365-2249.1996.60771.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1996.60771.x</ArticleId><ArticleId IdType="pmc">PMC2200444</ArticleId><ArticleId IdType="pubmed">9099922</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.W., Onodera T., Jenson A.B., Notkins A.L. Virus-induced diabetes mellitus. XI. Replication of coxsackie B3 virus in human pancreatic beta cell cultures. Diabetes. 1978;27:778–781. doi: 10.2337/diab.27.7.778.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.27.7.778</ArticleId><ArticleId IdType="pubmed">350678</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen H., Oikarinen S., Nurminen N., Laitinen O.H., Huhtala H., Lehtonen J., Ruokoranta T., Hankaniemi M.M., Lecouturier V., Almond J.W., et al. Detection of enteroviruses in stools precedes islet autoimmunity by several months: Possible evidence for slowly operating mechanisms in virus-induced autoimmunity. Diabetologia. 2017;60:424–431. doi: 10.1007/s00125-016-4177-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-4177-z</ArticleId><ArticleId IdType="pubmed">28070615</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse Z.J., Simister R.L., Crowe S.A., Horwitz M.S., Osborne L.C. Virus induced dysbiosis promotes type 1 diabetes onset. Front. Immunol. 2023;14:1096323. doi: 10.3389/fimmu.2023.1096323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1096323</ArticleId><ArticleId IdType="pmc">PMC9892191</ArticleId><ArticleId IdType="pubmed">36742327</ArticleId></ArticleIdList></Reference><Reference><Citation>Viskari H., Oikarinen S., Hoppu S., Vuorinen T., Huhtala H., Toppari J., Veijola R., Ilonen J., Knip M., Hyöty H. Live attenuated enterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes: Prospective cohort study. Diabetologia. 2018;61:203–209. doi: 10.1007/s00125-017-4410-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4410-4</ArticleId><ArticleId IdType="pubmed">28866779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasquinha M.T., Lasrado N., Sur M., Mone K., Qiu H., Riethoven J.J., Sobel R.A., Reddy J. A Monovalent Mt10-CVB3 Vaccine Prevents CVB4-Accelerated Type 1 Diabetes in NOD Mice. Vaccines. 2022;11:76. doi: 10.3390/vaccines11010076.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010076</ArticleId><ArticleId IdType="pmc">PMC9864234</ArticleId><ArticleId IdType="pubmed">36679922</ArticleId></ArticleIdList></Reference><Reference><Citation>el-Reshaid K., al-Mofti S., Stepic N.R. Induction of INS resistance by autoantibodies to INS receptors following on an acute Coxsackie B4 infection. Diabetes Res. Clin. Pract. 1994;25:207–210. doi: 10.1016/0168-8227(94)90010-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8227(94)90010-8</ArticleId><ArticleId IdType="pubmed">7851276</ArticleId></ArticleIdList></Reference><Reference><Citation>Boettler T., von Herrath M. Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Rev. Clin. Immunol. 2011;7:45–53. doi: 10.1586/eci.10.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eci.10.91</ArticleId><ArticleId IdType="pmc">PMC3077770</ArticleId><ArticleId IdType="pubmed">21162649</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.W., Taylor G., Basid A. The effect of pertussis vaccine on the INS-dependent diabetes induced by streptozotocin in ice. Pediatr. Res. 1984;18:221–226. doi: 10.1203/00006450-198402000-00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/00006450-198402000-00021</ArticleId><ArticleId IdType="pubmed">6366724</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomaguchi H., Yogi Y., Kawatsu K., Okamura H., Ozawa Y., Kasatani T. Prevention of diabetes in non-obese diabetic mice by a single immunization with Mycobacterium leprae. Nihon Hansenbyo Gakkai Zasshi. 2002;71:31–38. doi: 10.5025/hansen.71.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.5025/hansen.71.31</ArticleId><ArticleId IdType="pubmed">11979756</ArticleId></ArticleIdList></Reference><Reference><Citation>Silveira P.A., Baxter A.G. The NOD mouse as a model of SLE. Autoimmunity. 2001;34:53–64. doi: 10.3109/08916930108994126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916930108994126</ArticleId><ArticleId IdType="pubmed">11681493</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L., Shan K., Pan L.L., Feng N., Lv Z., Sun Y., Li J., Wu C., Zhang H., Chen W., et al. Clostridium butyricum CGMCC0313.1 Protects against Autoimmune Diabetes by Modulating Intestinal Immune Homeostasis and Inducing Pancreatic Regulatory T Cells. Front. Immunol. 2017;8:1345. doi: 10.3389/fimmu.2017.01345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01345</ArticleId><ArticleId IdType="pmc">PMC5654235</ArticleId><ArticleId IdType="pubmed">29097999</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovi K.S., Bajinka O., Conteh I. Evidence and possible mechanisms of probiotics in the management of type 1 diabetes mellitus. J. Diabetes Metab. Disord. 2022;21:1081–1094. doi: 10.1007/s40200-022-01006-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40200-022-01006-2</ArticleId><ArticleId IdType="pmc">PMC9167374</ArticleId><ArticleId IdType="pubmed">35673472</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz M.S., Bradley L.M., Harbertson J., Krahl T., Lee J., Sarvetnick N. Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry. Nat. Med. 1998;4:781–785. doi: 10.1038/nm0798-781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0798-781</ArticleId><ArticleId IdType="pubmed">9662368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sané F., Moumna I., Hober D. Group B COX and autoimmunity: Focus on Type 1 diabetes. Expert Rev. Clin. Immunol. 2011;7:357–366. doi: 10.1586/eci.11.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eci.11.11</ArticleId><ArticleId IdType="pubmed">21595602</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippi C., von Herrath M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell. Immunol. 2005;233:125–132. doi: 10.1016/j.cellimm.2005.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2005.04.009</ArticleId><ArticleId IdType="pubmed">15963965</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R. Molecular complementarity III. peptide complementarity as a basis for peptide receptor evolution: A bioinformatic case study of INS, glucagon and gastrin. J. Theor. Biol. 2002;218:71–84. doi: 10.1006/jtbi.2002.3056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jtbi.2002.3056</ArticleId><ArticleId IdType="pubmed">12297071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinesmith T., Turkette T., Root-Bernstein R. Rapid Non-Enzymatic Glycation of the INS Receptor under Hyperglycemic Conditions Inhibits INS Binding In Vitro: Implications for INS Resistance. Int. J. Mol. Sci. 2017;18:2602. doi: 10.3390/ijms18122602.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18122602</ArticleId><ArticleId IdType="pmc">PMC5751205</ArticleId><ArticleId IdType="pubmed">29207492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S.C., Chen Y., Bregoll L., Clemmings S.M., Kenyon N.S., Ricordi C., Hering B.J., Hafler D.A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an INS epitope. Nature. 2005;435:224–228. doi: 10.1038/nature03625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03625</ArticleId><ArticleId IdType="pubmed">15889096</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinovic-Bello I., Steinle A., Ziegler A.G., Schendel D.J. HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient. T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes. 1994;43:1318–1325. doi: 10.2337/diab.43.11.1318.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.43.11.1318</ArticleId><ArticleId IdType="pubmed">7926306</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R. Autoreactive T-cell receptor (Vbeta/D/Jbeta) sequences in diabetes are homologous to INS, glucagon, the INS receptor, and the glucagon receptor. J. Mol. Recognit. 2009;22:177–187. doi: 10.1002/jmr.930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmr.930</ArticleId><ArticleId IdType="pubmed">19051206</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R., Podufaly A. T Cell Receptor Variable Regions in Diabetes Bind to Each Other, to INS, Glucagon or INS Receptor, and to Their Antibodies. Open Autoimmun. J. 2012;4:10–22. doi: 10.2174/1876894601204010010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1876894601204010010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhave M.S., Hassanbhai A.M., Anand P., Luo K.Q., Teoh S.H. Effect of Heat-Inactivated Clostridium sporogenes and Its Conditioned Media on 3-Dimensional Colorectal Cancer Cell Models. Sci. Rep. 2015;5:15681. doi: 10.1038/srep15681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15681</ArticleId><ArticleId IdType="pmc">PMC4623472</ArticleId><ArticleId IdType="pubmed">26507312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondrashova A., Hyöty H. Role of viruses and other microbes in the pathogenesis of type 1 diabetes. Int. Rev. Immunol. 2014;33:284–295. doi: 10.3109/08830185.2014.889130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08830185.2014.889130</ArticleId><ArticleId IdType="pubmed">24611784</ArticleId></ArticleIdList></Reference><Reference><Citation>Real-Fernández F., Gallo A., Nuti F., Altamore L., Del Vescovo G.G., Traldi P., Ragazzi E., Rovero P., Lapolla A., Papini A.M. Cross-reactive peptide epitopes of Enterovirus Coxsackie B4 and human glutamic acid decarboxylase detecting anti-bodies in latent autoimmune diabetes in adults versus type 1 diabetes. Clin. Chim. Acta. 2021;515:73–79. doi: 10.1016/j.cca.2021.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.01.002</ArticleId><ArticleId IdType="pubmed">33422493</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazmi A., Nekoua M.P., Mercier A., Vergez I., Sane F., Alidjinou E.K., Hober D. Combating coxsackievirus B infections. Rev. Med. Virol. 2023;33:e2406. doi: 10.1002/rmv.2406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2406</ArticleId><ArticleId IdType="pubmed">36371612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotta F., Censini S., van Halteren A.G., Marselli L., Masini M., Dionisi S., Mosca F., Boggi U., Muda A.O., Del Prato S., et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc. Natl. Acad. Sci. USA. 2007;104:5115–5120. doi: 10.1073/pnas.0700442104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0700442104</ArticleId><ArticleId IdType="pmc">PMC1829272</ArticleId><ArticleId IdType="pubmed">17360338</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo T. Enterovirus infection and type 1 diabetes: Unraveling the crime scene. Clin. Exp. Immunol. 2019;195:15–24. doi: 10.1111/cei.13223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13223</ArticleId><ArticleId IdType="pmc">PMC6300647</ArticleId><ArticleId IdType="pubmed">30307605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylipaasto P., Klingel K., Lindberg A.M., Otonkoski T., Kandolf R., Hovi T., Roivainen M. Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells. Diabetologia. 2004;47:225–239. doi: 10.1007/s00125-003-1297-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-003-1297-z</ArticleId><ArticleId IdType="pubmed">14727023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.W., Horton J.L., Pang C.N.I., Jain K., Leung P., Isaacs S.R., Bull R.A., Luciani F., Wilkins M.R., Catteau J., et al. Higher abundance of enterovirus A species in the gut of children with islet auto-immunity. Sci. Rep. 2019;9:1749. doi: 10.1038/s41598-018-38368-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-38368-8</ArticleId><ArticleId IdType="pmc">PMC6370883</ArticleId><ArticleId IdType="pubmed">30741981</ArticleId></ArticleIdList></Reference><Reference><Citation>Batarseh H., Thompson R.A., Odugbesan O., Barnett A.H. INS receptor antibodies in diabetes mellitus. Clin. Exp. Immunol. 1988;71:85–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1541634</ArticleId><ArticleId IdType="pubmed">3280181</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca V., Khokher M.A., Dandona P. INS receptor antibodies causing steroid responsive diabetes mellitus in a patient with myositis. Br. Med. J. (Clin. Res. Ed.) 1984;288:1578. doi: 10.1136/bmj.288.6430.1578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.288.6430.1578</ArticleId><ArticleId IdType="pmc">PMC1441240</ArticleId><ArticleId IdType="pubmed">6426651</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron R., Elias D., de Jongh B.M., Bruining G.J., van Rood J.J., Schechter Y., Cohen I.R. Autoantibodies to the INS receptor in juvenile onset INS-dependent diabetes. Nature. 1983;303:817–818. doi: 10.1038/303817a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/303817a0</ArticleId><ArticleId IdType="pubmed">6346102</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias D., Bone A.J., Baird J.D., Cooke A., Cohen I.R. INS-mimicking anti-idioptypic antibodies in development of spontaneous autoimmune diabetes in BB/E rats. Diabetes. 1990;39:1467–1471. doi: 10.2337/diab.39.12.1467.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.39.12.1467</ArticleId><ArticleId IdType="pubmed">2245874</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonso G., Mallone R. Infectious triggers in type 1 diabetes: Is there a case for epitope mimicry? Diabetes Obes. Metab. 2013;15((Suppl. S3)):82–88. doi: 10.1111/dom.12166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12166</ArticleId><ArticleId IdType="pubmed">24003924</ArticleId></ArticleIdList></Reference><Reference><Citation>Roep B.O., Hiemstra H.S., Schloot N.C., De Vries R.R., Chaudhuri A., Behan P.O., Drijfhout J.W. Molecular mimicry in type 1 diabetes: Immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Ann. N. Y. Acad. Sci. 2002;958:163–165. doi: 10.1111/j.1749-6632.2002.tb02961.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2002.tb02961.x</ArticleId><ArticleId IdType="pubmed">12021098</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloot N.C., Willemen S.J., Duinkerken G., Drijfhout J.W., de Vries R.R., Roep B.O. Molecular mimicry in type 1 diabetes mellitus revisited: T-cell clones to GAD65 peptides with sequence homology to Coxsackie or proINS peptides do not crossreact with homologous counterpart. Hum. Immunol. 2001;62:299–309. doi: 10.1016/S0198-8859(01)00223-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0198-8859(01)00223-3</ArticleId><ArticleId IdType="pubmed">11295462</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreugdenhil G.R., Geluk A., Ottenhoff T.H., Melchers W.J., Roep B.O., Galama J.M. Molecular mimicry in diabetes mellitus: The homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule. Diabetologia. 1998;41:40–46. doi: 10.1007/s001250050864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001250050864</ArticleId><ArticleId IdType="pubmed">9498628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J., Said C., Franchi D., Dockstader P., Chatterjee N.K. Antibodies to glutamic acid decarboxylase and P2-C peptides in sera from coxsackie virus B4-infected mice and IDDM patients. Diabetes. 1994;43:1260–1266. doi: 10.2337/diab.43.10.1260.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.43.10.1260</ArticleId><ArticleId IdType="pubmed">7523207</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz M.S., Ilic A., Fine C., Rodriguez E., Sarvetnick N. Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J. Clin. Investig. 2002;109:79–87. doi: 10.1172/JCI0211198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0211198</ArticleId><ArticleId IdType="pmc">PMC150813</ArticleId><ArticleId IdType="pubmed">11781353</ArticleId></ArticleIdList></Reference><Reference><Citation>Narendran P., Williams A.J., Elsegood K., Leech N.J., Dayan C.M. Humoral and cellular immune responses to proINS in adults with newly diagnosed type 1 diabetes. Diabetes Metab. Res. Rev. 2003;19:52–59. doi: 10.1002/dmrr.332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.332</ArticleId><ArticleId IdType="pubmed">12592644</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin A., Zhao C.W., Wegmann K.W., Hickley W.F. Experimental autoimmune insulitis. Induction by T lymphocytes specific for a peptide of proINS. Am. J. Pathol. 1995;147:845–857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1870961</ArticleId><ArticleId IdType="pubmed">7545875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloot N.C., Willemen S., Duinkerken G., de Vries R.R., Roep B.O. Cloned T cells from a recent onset IDDM patient reactive with INS B-chain. J. Autoimmun. 1998;11:169–175. doi: 10.1006/jaut.1997.0183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jaut.1997.0183</ArticleId><ArticleId IdType="pubmed">9650096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., Yu L., Wegmann D.R., Hutton J.C., Elliott J.F., et al. Prime role for an INS epitope in the development of type 1 diabetes in NOD mice. Nature. 2005;435:220–223. doi: 10.1038/nature03523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03523</ArticleId><ArticleId IdType="pmc">PMC1364531</ArticleId><ArticleId IdType="pubmed">15889095</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkse G.G., Tysma O.H., Bergen C.A., Kester M.G., Ossendorp F., van Veelen P.A., Keymeulen B., Pipeleers D., Drijfhout J.W., Roep B.O. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc. Natl. Acad. Sci. USA. 2005;102:18425–18430. doi: 10.1073/pnas.0508621102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508621102</ArticleId><ArticleId IdType="pmc">PMC1317949</ArticleId><ArticleId IdType="pubmed">16339897</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkse G.G., Boitard C., Tree T.I., Peakman M., Roep B.O. HLA class I epitope discovery in type 1 diabetes: Independent and reproducible identification of proINS epitopes of CD8 T cells-report of the IDS T Cell Workshop Committee. Ann. N. Y. Acad. Sci. 2006;1079:19–23. doi: 10.1196/annals.1375.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1375.003</ArticleId><ArticleId IdType="pubmed">17130527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin D.U., Pleasic S.M., Shapiro J.A., Yoo-Warren H., Oles J., Hicks J.M., Goldstein D.E., Rae P.M. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunol. 1994;152:3183–3188. doi: 10.4049/jimmunol.152.6.3183.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.152.6.3183</ArticleId><ArticleId IdType="pubmed">8144912</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarchum I., Baker J.C., Yamada T., Takaki T., Marron M.P., Serreze D.V., DiLorenzo T.P. In vivo cytotoxicity of INS-specific CD8+ T-cells in HLA-A*0201 transgenic NOD mice. Diabetes. 2007;56:2551–2560. doi: 10.2337/db07-0332.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db07-0332</ArticleId><ArticleId IdType="pubmed">17620420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacio E., Lampasona V., Genovese S., Ferrari M., Bosi E. Identification of protein tyrosine phosphotase-like IA-2 (islet cell antigen 512) as the INS-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J. Immunol. 1995;155:5419–5426. doi: 10.4049/jimmunol.155.11.5419.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.155.11.5419</ArticleId><ArticleId IdType="pubmed">7594559</ArticleId></ArticleIdList></Reference><Reference><Citation>Solimena M., Dirkx RJr Hermel J.-M., Pleasic-Williams S., Shapiro J.A., Caron L., Rabin D.U. ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J. 1996;15:2102–2114. doi: 10.1002/j.1460-2075.1996.tb00564.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1996.tb00564.x</ArticleId><ArticleId IdType="pmc">PMC450132</ArticleId><ArticleId IdType="pubmed">8641276</ArticleId></ArticleIdList></Reference><Reference><Citation>Honeyman M.C., Stone N.L., Harrison L.C. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: Potential for mimicry with rotavirus and other environmental agents. Mol. Med. 1998;4:231–239. doi: 10.1007/BF03401920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03401920</ArticleId><ArticleId IdType="pmc">PMC2230363</ArticleId><ArticleId IdType="pubmed">9606176</ArticleId></ArticleIdList></Reference><Reference><Citation>Iddings A.C., Shenoi A.N., Morales Pozzo A., Kiessling S.G. Hemolytic uremic syndrome complicated by Clostridium septicum bacteremia and new-onset type 1 diabetes mellitus. Report of a case. Clin. Nephrol. 2017;87:207–211. doi: 10.5414/CN109049.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CN109049</ArticleId><ArticleId IdType="pubmed">28211788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzai S., Rifai A.O., Webb S., Rifai K., Reiner A. Probable Clostridium septicum pneumocephalus in a user of natural remedies with newly diagnosed diabetes mellitus type 1. IDCases. 2019;17:e00581. doi: 10.1016/j.idcr.2019.e00581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2019.e00581</ArticleId><ArticleId IdType="pmc">PMC6610224</ArticleId><ArticleId IdType="pubmed">31312601</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamshidi P., Hasanzadeh S., Tahvildari A., Farsi Y., Arbabi M., Mota J.F., Sechi L.A., Nasiri M.J. Is there any association be-tween gut microbiota and type 1 diabetes? A systematic review. Gut Pathog. 2019;11:49. doi: 10.1186/s13099-019-0332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13099-019-0332-7</ArticleId><ArticleId IdType="pmc">PMC6791003</ArticleId><ArticleId IdType="pubmed">31636716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Xu S., Cavagnaro M.J., Zhang W., Shi J. Quantitative Analysis and Visualization of the Interaction Between Intestinal Microbiota and Type 1 Diabetes in Children Based on Multi-Databases. Front. Pediatr. 2021;9:752250. doi: 10.3389/fped.2021.752250.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.752250</ArticleId><ArticleId IdType="pmc">PMC8715853</ArticleId><ArticleId IdType="pubmed">34976889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinek O., Kramna L., Mazankova K., Odeh R., Alassaf A., Ibekwe M.U., Ahmadov G., Elmahi B.M.E., Mekki H., Lebl J., et al. The bacteriome at the onset of type 1 diabetes: A study from four geographically distant African and Asian countries. Diabetes Res. Clin. Pract. 2018;144:51–62. doi: 10.1016/j.diabres.2018.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.08.010</ArticleId><ArticleId IdType="pubmed">30121305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatanen T., Franzosa E.A., Schwager R., Tripathi S., Arthur T.D., Vehik K., Lernmark Å., Hagopian W.A., Rewers M.J., She J.X., et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature. 2018;562:589–594. doi: 10.1038/s41586-018-0620-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0620-2</ArticleId><ArticleId IdType="pmc">PMC6296767</ArticleId><ArticleId IdType="pubmed">30356183</ArticleId></ArticleIdList></Reference><Reference><Citation>Endesfelder D., Engel M., Davis-Richardson A.G., Ardissone A.N., Achenbach P., Hummel S., Winkler C., Atkinson M., Schatz D., Triplett E., et al. Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome. 2016;4:17. doi: 10.1186/s40168-016-0163-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-016-0163-4</ArticleId><ArticleId IdType="pmc">PMC4845316</ArticleId><ArticleId IdType="pubmed">27114075</ArticleId></ArticleIdList></Reference><Reference><Citation>Traversi D., Scaioli G., Rabbone I., Carletto G., Ferro A., Franchitti E., Carrera D., Savastio S., Cadario F., Siliquini R., et al. Gut microbiota, behavior, and nutrition after type 1 diabetes diagnosis: A longitudinal study for supporting data in the metabolic control. Front. Nutr. 2022;9:968068. doi: 10.3389/fnut.2022.968068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.968068</ArticleId><ArticleId IdType="pmc">PMC9763620</ArticleId><ArticleId IdType="pubmed">36562032</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R. Autoimmunity and the microbiome: T-cell receptor mimicry of “self” and microbial antigens mediates self tolerance in holobionts: The concepts of “holoim-munity” (TcR-mediated tolerance for the holobiont) and “holoautoimmunity” (loss of tol-erance for the holobiont) are introduced. Bioessays. 2016;38:1068–1083. doi: 10.1002/bies.201600083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.201600083</ArticleId><ArticleId IdType="pmc">PMC7161894</ArticleId><ArticleId IdType="pubmed">27594308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudy G., Stone N., Harrison L.C., Colman P.G., McNair P., Brusic V., French M.B., Honeyman M.C., Tait B., Lew A.M. Similar peptides from two beta cell autoantigens, proINS and glutamic acid decarboxylase, stimulate T cells of individuals at risk for INS-dependent diabetes. Mol. Med. 1995;1:625–633. doi: 10.1007/BF03401603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03401603</ArticleId><ArticleId IdType="pmc">PMC2229979</ArticleId><ArticleId IdType="pubmed">8529129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara N., Alkanani A.K., Ir D., Robertson C.E., Wagner B.D., Frank D.N., Zipris D. Prevention of virus-induced type 1 diabetes with antibiotic therapy. J. Immunol. 2012;189:3805–3814. doi: 10.4049/jimmunol.1201257.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201257</ArticleId><ArticleId IdType="pubmed">22988033</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lorenzo T.P., Peakman M., Roep B.O. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 2007;148:1–16. doi: 10.1111/j.1365-2249.2006.03244.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2006.03244.x</ArticleId><ArticleId IdType="pmc">PMC1868845</ArticleId><ArticleId IdType="pubmed">17349009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanca A., Palomba A., Fraumene C., Manghina V., Silverman M., Uzzau S. Clostridial Butyrate Biosynthesis Enzymes Are Significantly Depleted in the Gut Microbiota of Nonobese Diabetic Mice. mSphere. 2018;3:e00492-18. doi: 10.1128/mSphere.00492-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00492-18</ArticleId><ArticleId IdType="pmc">PMC6200989</ArticleId><ArticleId IdType="pubmed">30355671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L., Li D., Feng N., Shamoon M., Sun Z., Ding L., Zhang H., Chen W., Sun J., Chen Y.Q. Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice. Sci. Rep. 2017;7:7046. doi: 10.1038/s41598-017-07335-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-07335-0</ArticleId><ArticleId IdType="pmc">PMC5539151</ArticleId><ArticleId IdType="pubmed">28765642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Li Y.Y., Liu Y. Effect of fecal microbiota transplantation on type 1 diabetes mellitus in non-obese diabetic mice and its underlying mechanism. Zhonghua Yi Xue Za Zhi. 2022;102:1224–1231. doi: 10.3760/cma.j.cn112137-20210907-02043. (In Chinese)</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112137-20210907-02043</ArticleId><ArticleId IdType="pubmed">35462505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown K., Godovannyi A., Ma C., Zhang Y., Ahmadi-Vand Z., Dai C., Gorzelak M.A., Chan Y., Chan J.M., Lochner A., et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME J. 2016;10:321–332. doi: 10.1038/ismej.2015.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2015.114</ArticleId><ArticleId IdType="pmc">PMC4737925</ArticleId><ArticleId IdType="pubmed">26274050</ArticleId></ArticleIdList></Reference><Reference><Citation>Depestel D.D., Aronoff D.M. Epidemiology of Clostridium difficile infection. J. Pharm. Pract. 2013;26:464–475. doi: 10.1177/0897190013499521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0897190013499521</ArticleId><ArticleId IdType="pmc">PMC4128635</ArticleId><ArticleId IdType="pubmed">24064435</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn E., Andersson F.L., Madin-Warburton M. Burden of Clostridioides difficile infection (CDI)—A systematic review of the epidemiology of primary and recurrent CDI. BMC Infect. Dis. 2021;21:456. doi: 10.1186/s12879-021-06147-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06147-y</ArticleId><ArticleId IdType="pmc">PMC8135979</ArticleId><ArticleId IdType="pubmed">34016040</ArticleId></ArticleIdList></Reference><Reference><Citation>Tougas S.R., Lodha N., Vandermeer B., Lorenzetti D.L., Tarr P.I., Tarr G.A.M., Chui L., Vanderkooi O.G., Freedman S.B. Prevalence of Detection of Clostridioides difficile Among Asymptomatic Children: A Systematic Review and Meta-analysis. JAMA Pediatr. 2021;175:e212328. doi: 10.1001/jamapediatrics.2021.2328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.2328</ArticleId><ArticleId IdType="pmc">PMC8329794</ArticleId><ArticleId IdType="pubmed">34338715</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennhofer S.A., Rogawski McQuade E.T., Liu J., Guerrant R.L., Platts-Mills J.A., Warren C.A. Clostridioides difficile colonization among very young children in resource-limited settings. Clin. Microbiol. Infect. 2022;28:996–1002. doi: 10.1016/j.cmi.2022.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.022</ArticleId><ArticleId IdType="pmc">PMC9240321</ArticleId><ArticleId IdType="pubmed">35150876</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero J.R. Pediatric group B COX infections. Curr. Top. Microbiol. Immunol. 2008;323:223–239. doi: 10.1007/978-3-540-75546-3_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-75546-3_10</ArticleId><ArticleId IdType="pubmed">18357772</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetsuriani N., Lamonte-Fowlkes A., Oberst S., Pallansch M.A., Centers for Disease Control and Prevention Enterovirus surveillance—United States, 1970–2005. MMWR Surveill. Summ. 2006;55:1–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971890</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer L., Moreni G., Wolthers K.C., Pajkrt D. World-Wide Prevalence and Genotype Distribution of Enteroviruses. Viruses. 2021;13:434. doi: 10.3390/v13030434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030434</ArticleId><ArticleId IdType="pmc">PMC7999254</ArticleId><ArticleId IdType="pubmed">33800518</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J., Cao Z., Liu H., Xu J., Zhao L., Gao L., Zuo Z., Song Y., Han Z., Zhang Y., et al. Epidemiology of hand, foot, and mouth disease and the genetic characteristics of COX A16 in Taiyuan, Shanxi, China from 2010 to 2021. Front. Cell. Infect. Microbiol. 2022;12:1040414. doi: 10.3389/fcimb.2022.1040414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.1040414</ArticleId><ArticleId IdType="pmc">PMC9692002</ArticleId><ArticleId IdType="pubmed">36439232</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie R.D., Evans-Molina C., Freund-Brown J., Buzzetti R., Dabelea D., Gillespie K.M., Goland R., Jones A.G., Kacher M., Phillips L.S., et al. Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care. 2021;44:2449–2456. doi: 10.2337/dc21-0770.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc21-0770</ArticleId><ArticleId IdType="pmc">PMC8546280</ArticleId><ArticleId IdType="pubmed">34670785</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobasseri M., Shirmohammadi M., Amiri T., Vahed N., Hosseini Fard H., Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis. Health Promot. Perspect. 2020;10:98–115. doi: 10.34172/hpp.2020.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/hpp.2020.18</ArticleId><ArticleId IdType="pmc">PMC7146037</ArticleId><ArticleId IdType="pubmed">32296622</ArticleId></ArticleIdList></Reference><Reference><Citation>Moltchanova E.V., Schreier N., Lammi N., Karvonen M. Seasonal variation of diagnosis of Type 1 diabetes mellitus in children worldwide. Diabet. Med. 2009;26:673–678. doi: 10.1111/j.1464-5491.2009.02743.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-5491.2009.02743.x</ArticleId><ArticleId IdType="pubmed">19573115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci S., Perugia F., Piccini B., Lodi L., Pegoraro F., Giovannini M., Rombolà G., Perferi G., Toni S., Azzari C. DR4/DQ2 haplotype confers susceptibility to T1DM with early clinical disease onset: A retrospective analysis in a tertiary-care hospital in Italy. PLoS ONE. 2022;17:e0276896. doi: 10.1371/journal.pone.0276896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0276896</ArticleId><ArticleId IdType="pmc">PMC9678300</ArticleId><ArticleId IdType="pubmed">36409706</ArticleId></ArticleIdList></Reference><Reference><Citation>Morran M.P., Vonberg A., Khadra A., Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. Mol. Asp. Med. 2015;42:42–60. doi: 10.1016/j.mam.2014.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2014.12.004</ArticleId><ArticleId IdType="pmc">PMC4548800</ArticleId><ArticleId IdType="pubmed">25579746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler A.G., Kick K., Bonifacio E., Haupt F., Hippich M., Dunstheimer D., Lang M., Laub O., Warncke K., Lange K., et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA. 2020;323:339–351. doi: 10.1001/jama.2019.21565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.21565</ArticleId><ArticleId IdType="pmc">PMC6990943</ArticleId><ArticleId IdType="pubmed">31990315</ArticleId></ArticleIdList></Reference><Reference><Citation>Raab J., Haupt F., Scholz M., Matzke C., Warncke K., Lange K., Assfalg R., Weininger K., Wittich S., Löbner S., et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: Design and initial results of the Fr1da study. BMJ Open. 2016;6:e011144. doi: 10.1136/bmjopen-2016-011144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011144</ArticleId><ArticleId IdType="pmc">PMC4874167</ArticleId><ArticleId IdType="pubmed">27194320</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo M.J., Steck A.K., Pugliese A. Genetics of type 1 diabetes. Pediatr. Diabetes. 2018;19:346–353. doi: 10.1111/pedi.12597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12597</ArticleId><ArticleId IdType="pmc">PMC5918237</ArticleId><ArticleId IdType="pubmed">29094512</ArticleId></ArticleIdList></Reference><Reference><Citation>Steck A.K., Rewers M.J. Genetics of type 1 diabetes. Clin. Chem. 2011;57:176–185. doi: 10.1373/clinchem.2010.148221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2010.148221</ArticleId><ArticleId IdType="pmc">PMC4874193</ArticleId><ArticleId IdType="pubmed">21205883</ArticleId></ArticleIdList></Reference><Reference><Citation>Steck A.K., Armstrong T.K., Babu S.R., Eisenbarth G.S., Type 1 Diabetes Genetics Consortium Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. Diabetes. 2011;60:1045–1049. doi: 10.2337/db10-1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-1419</ArticleId><ArticleId IdType="pmc">PMC3046823</ArticleId><ArticleId IdType="pubmed">21307077</ArticleId></ArticleIdList></Reference><Reference><Citation>Carré A., Vecchio F., Flodstrom-Tullberg M., You S., Mallone R. COX and type 1 diabetes: Diabetogenic mechanisms and implications for prevention. Endocr. Rev. 2023:bnad007. doi: 10.1210/endrev/bnad007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnad007</ArticleId><ArticleId IdType="pubmed">36884282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan H., Hosomi K., Kunisawa J. Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system. Vaccine. 2019;37:6232–6239. doi: 10.1016/j.vaccine.2019.08.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.08.032</ArticleId><ArticleId IdType="pubmed">31466706</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosomi K., Hinenoya A., Suzuki H., Nagatake T., Nishino T., Tojima Y., Hirata S.I., Matsunaga A., Kondoh M., Yamasaki S., et al. Development of a bivalent food poisoning vaccine: Augmented antigenicity of the C-terminus of Clostridium perfringens enterotoxin by fusion with the B subunit of Escherichia coli Shiga toxin 2. Int. Immunol. 2019;31:91–100. doi: 10.1093/intimm/dxy071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxy071</ArticleId><ArticleId IdType="pubmed">30329068</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues R.R., Ferreira M.R.A., Kremer F.S., Donassolo R.A., Júnior C.M., Alves M.L.F., Conceição F.R. Recombinant Vaccine Design against Clostridium spp. Toxins Using Immunoinformatics Tools. Methods Mol. Biol. 2022;2412:457–470. doi: 10.1007/978-1-0716-1892-9_25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1892-9_25</ArticleId><ArticleId IdType="pubmed">34918262</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadh M.J., Lafi F.F., Dahadha A.A., Albannan M.S. Immunogenicity of a newly developed vaccine against Clostridium perfringens alpha-toxin in rabbits and cattle. Vet. World. 2022;15:1617–1623. doi: 10.14202/vetworld.2022.1617-1623.</Citation><ArticleIdList><ArticleId IdType="doi">10.14202/vetworld.2022.1617-1623</ArticleId><ArticleId IdType="pmc">PMC9394151</ArticleId><ArticleId IdType="pubmed">36185515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti F., Scalia G., Lunetta M., Condorelli F., Di Mauro M., Barcellini W., Stracuzzi S., Pagano M., Meroni P.L. Correlation between islet cell antibodies and anti-cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (INS-dependent) diabetic patients. Clin. Immunol. Immunopathol. 1990;55:139–147. doi: 10.1016/0090-1229(90)90075-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-1229(90)90075-2</ArticleId><ArticleId IdType="pubmed">2155076</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoneda S., Imagawa A., Fukui K., Uno S., Kozawa J., Sakai M., Yumioka T., Iwahashi H., Shimomura I. A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation. J. Clin. Endocrinol. Metab. 2017;102:2394–2400. doi: 10.1210/jc.2016-4029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2016-4029</ArticleId><ArticleId IdType="pubmed">28398495</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarnisalo J., Veijola R., Vainionpää R., Simell O., Knip M., Ilonen J. Cytomegalovirus infection in early infancy: Risk of induction and progression of autoimmunity associated with type 1 diabetes. Diabetologia. 2008;51:769–772. doi: 10.1007/s00125-008-0945-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-008-0945-8</ArticleId><ArticleId IdType="pubmed">18278478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ataei-Pirkooh A., Tehrani M., Keyvani H., Esghaei M., Tavakoli A., Nikmanesh B., Farahmand M., Ghaffari H., Monavari S.H. Rotavirus Infection Enhances Levels of Autoantibodies Against Islet Cell Antigens GAD65 and IA-2 in Children with Type 1 Diabetes. Fetal Pediatr. Pathol. 2019;38:103–111. doi: 10.1080/15513815.2018.1547338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15513815.2018.1547338</ArticleId><ArticleId IdType="pubmed">30588857</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudensky Y., Preston-Hurlburt P., Hong S.C., Barlow A., Janeway C.A., Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature. 1991;353:622–627. doi: 10.1038/353622a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/353622a0</ArticleId><ArticleId IdType="pubmed">1656276</ArticleId></ArticleIdList></Reference><Reference><Citation>Suri A., Lovitch S.B., Unanue E.R. The wide diversity and complexity of peptides bound to class II MHC molecules. Curr. Opin. Immunol. 2006;18:70–77. doi: 10.1016/j.coi.2005.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2005.11.002</ArticleId><ArticleId IdType="pubmed">16316750</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham M.W., McCormack J.M., Fenderson P.G., Ho M.K., Beachey E.H., Dale J.B. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J. Immunol. 1989;143:2677–2683. doi: 10.4049/jimmunol.143.8.2677.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.143.8.2677</ArticleId><ArticleId IdType="pubmed">2677144</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R. Human Immunodeficiency Virus Proteins Mimic Human T Cell Receptors Inducing Cross-Reactive Antibodies. Int. J. Mol. Sci. 2017;18:2091. doi: 10.3390/ijms18102091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18102091</ArticleId><ArticleId IdType="pmc">PMC5666773</ArticleId><ArticleId IdType="pubmed">28972547</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R., Vonck J., Podufaly A. Antigenic complementarity between coxsackie virus and streptococcus in the induction of rheumatic heart disease and autoimmune myocarditis. Autoimmunity. 2009;42:1–16. doi: 10.1080/08916930802208540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930802208540</ArticleId><ArticleId IdType="pubmed">18608177</ArticleId></ArticleIdList></Reference><Reference><Citation>Root-Bernstein R., Huber J., Ziehl A. Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies. Int. J. Mol. Sci. 2022;23:11500. doi: 10.3390/ijms231911500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911500</ArticleId><ArticleId IdType="pmc">PMC9569991</ArticleId><ArticleId IdType="pubmed">36232795</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>